Back to Search
Start Over
Analgesia in Transcutaneous Laryngeal Botulinum Toxin Injections: A Randomized Crossover Trial.
- Source :
-
The Laryngoscope [Laryngoscope] 2024 May; Vol. 134 (5), pp. 2277-2281. Date of Electronic Publication: 2023 Dec 29. - Publication Year :
- 2024
-
Abstract
- Objectives: There is an absence of data in the literature regarding methods to improve the patient experience during the performance of awake in-office laryngeal injections. This study sought to evaluate whether the use of local anesthetic or a vibrating instrument decreased overall pain experienced by patients with laryngeal dystonia, frequently referred to as spasmodic dysphonia (SD), undergoing transcervical botulinum toxin injections.<br />Methods: This was an unblinded, prospective randomized control trial with a crossover design where each patient received transcutaneous transcricothyroid injection of botulinum toxin with alternating use of no anesthesia, local anesthesia (2% lidocaine in 1:100,000 epinephrine), and vibrating instrument in three consecutive laryngeal injections to treat adductor SD. Patients were randomized to the order they received these treatments. Patients measured pain on a 0-10 visual analogue scale (VAS) and selected their preferred technique after receiving all three analgesic modalities.<br />Results: Thirty-two patients completed the study. There was no statistically significant difference in pain between the three analgesic techniques (pā=ā0.38). The most preferred analgesic technique was the vibrating wand (44% (14/32)). Lidocaine was the second most preferred (37% (12/32)) and 19% (6/32) of patients preferred nothing. When combining the wand and nothing groups, 63% of patients preferred one of these two methods (95% exact CI: 44%-79%).<br />Conclusion: There was no statistically significant difference in median pain experienced by patients during laryngeal botulinum toxin injection between these different analgesic modalities. More than half of the patients selected a preference for a technique that did not include lidocaine. This data supports individualization of analgesia during transcutaneous laryngeal injections.<br />Level of Evidence: 2 Laryngoscope, 134:2277-2281, 2024.<br /> (© 2023 The American Laryngological, Rhinological and Otological Society, Inc.)
Details
- Language :
- English
- ISSN :
- 1531-4995
- Volume :
- 134
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- The Laryngoscope
- Publication Type :
- Academic Journal
- Accession number :
- 38157199
- Full Text :
- https://doi.org/10.1002/lary.31208